Tea consumption has been classically linked to prevention of heart diseases, cancer, obesity, diabetes and other conditions. Now, drinking tea at least three times a week is linked with a longer and healthier life, according to a study published today in the European Journal of Preventive Cardiology. The analysis included 100,902 participants of the China-PAR project2 with no history of heart attack, stroke, or cancer. Participants were classified into two groups: habitual tea drinkers (three or more times a week) and never or non-habitual tea drinkers (less than three times a week) and followed-up for a median of 7.3 years. Habitual tea consumption was associated with more healthy years of life and longer life expectancy. For example, the analyses estimated that 50-year-old habitual tea drinkers would develop coronary heart disease and stroke 1.41 years later and live 1.26 years longer than those who never or seldom drank tea.
Compared with never or non-habitual tea drinkers, habitual tea consumers had a 20% lower risk of incident heart disease and stroke, 22% lower risk of fatal heart disease and stroke, and 15% decreased risk of all-cause death. The potential influence of changes in tea drinking behaviour were analysed in a subset of 14,081 participants with assessments at two time points. The average duration between the two surveys was 8.2 years, and the median follow-up after the second survey was 5.3 years. Habitual tea drinkers who maintained their habit in both surveys had a 39% lower risk of incident heart disease and stroke, 56% lower risk of fatal heart disease and stroke, and 29% decreased risk of all-cause death compared to consistent never or non-habitual tea drinkers.
In a subanalysis by type of tea, drinking green tea was linked with approximately 25% lower risks for incident heart disease and stroke, fatal heart disease and stroke, and all-cause death. However, no significant associations were observed for black tea. Scientists noted that a preference for green tea is unique to East Asia. Indeed, 49% of habitual tea drinkers consumed green tea most frequently, while only 8% preferred black tea. The small proportion of habitual black tea drinkers might make it more difficult to observe robust associations, but study findings hint at a differential effect between tea types. Two factors may be at play. First, green tea is a rich source of polyphenols which protect against cardiovascular disease and its risk factors including high blood pressure and dyslipidaemia. Black tea is fully fermented and during this process polyphenols are oxidised into pigments and may lose their antioxidant effects.
Second, black tea is often served with milk, which previous research has shown may counteract the favourable health effects of tea on vascular function. First author Dr. Xinyan Wang, working at the Chinese Academy of Medical Sciences of Beijing, commented: “Habitual tea consumption is associated with lower risks of cardiovascular disease and all-cause death. The favourable health effects are the most robust for green tea and for long-term habitual tea drinkers.” Senior author Dr. Dongfeng Gu, added: “The protective effects of tea were most pronounced among the consistent habitual tea drinking group. Mechanism studies have suggested that the main tea polyphenols, are not stored in the body long-term. Thus, frequent tea intake over an extended period may be necessary for the cardioprotective effect”.
Gender-specific analyses showed that the protective effects of habitual tea consumption were pronounced and robust across different outcomes for men, but only modest for women. Indeed, scientists noticed that one reason might be that 48% of men were habitual tea consumers compared to just 20% of women. Secondly, women had much lower incidence of, and mortality from, heart disease and stroke. These differences made it more likely to find statistically significant results among men. The authors concluded that randomised trials are warranted to confirm the findings and provide evidence for dietary guidelines and lifestyle recommendations.
- Edited by Dr. Gianfrancesco Cormaci, PhD; specialist in Clinical Biochemistry.
Wang X et al. Eur J Prevent Cardiol 2020; 2047487319894685.
Chen Y, Wu Y et al. Oncotarget. 2017 Jun 6; 8(23):37367-376.
Liu J et al. Zhou M. Eur J Epidemiol. 2016 Sep; 31(9):853-65.
Dott. Gianfrancesco Cormaci
Ultimi post di Dott. Gianfrancesco Cormaci (vedi tutti)
- I farmaci ACE-inibitori: cosa sono, come funzionano e per cosa vengono utilizzati - Ottobre 6, 2022
- Anticoagulanti ed antiaggreganti piastrinici: una rassegna di base per sapere cosa sono e come si usano - Ottobre 6, 2022
- Retinoblastoma gets “viewed” from within: and the nuclear receptor hopes for drug solution sightin’ - Ottobre 6, 2022
- Vasculopatie e tumori che condividono meccanismi comuni: sulla comprensione di chi “spiana il terreno” per chi - Ottobre 6, 2022
- Ricerche sulla predisposizione all’embolia venosa nei tumori: le correlazioni con i gruppi sanguigni - Ottobre 6, 2022